Molbio Diagnostics came to market through an IPO that opened on 10 August 2026 and closed on 12 August 2026, and the shares listed on 17 August 2026 on BSE, NSE. The price band was ₹768 to ₹807 per share and one lot was 18 shares, so the minimum application was ₹14,526. The issue size was ₹939.7 crore. It combined a fresh issue of new shares with an offer for sale by existing shareholders.
It listed at ₹980, a gain of 21.4% against the issue price of ₹807. Kfin Technologies Ltd was the registrar to the issue, and Kotak Mahindra Capital Co.Ltd., IIFL Capital Services Ltd., Jefferies India Pvt.Ltd., Motilal Oswal Investment Advisors Ltd were the lead managers.
As of 12 August 2026.
| Day |
|---|
| 1 |
| 2 |
| 3 |
Overall the issue was subscribed 70.26 times.
Incorporated in October 2000, Molbio Diagnostics Limited is an international POC (Point of Care) molecular diagnostics company providing the research, development, manufacture, and marketing of rapid diagnostic tools for various infectious and non-communicable diseases. The company owns proprietary 'Truenat' platform – it is a portable, battery-driven PCR-based molecular diagnostics system that produces reliable tests in an hour.
Molbio provides molecular diagnostics solutions for more than 30 diseases through 43 diagnostic tests that include tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. Besides, the company also provides radiology, digital pathology, and breast health screening services through its subsidiaries and strategic partnerships while continuously broadening the diagnostics products range through advanced R&D operations.
There are six manufacturing sites of Molbio located in India and the company provides its products to over 90 countries worldwide through government health programs, diagnostic laboratories, hospitals, and other international healthcare companies. Supported with its patent portfolio, international certification, and strategic acquisitions, Molbio is recognized as the leader in innovations in molecular diagnostics. As of March 31, 2026, Molbio had 1,225 employees on permanent positions in research and development, manufacturing, quality control, sales, financial, and corporate departments.
As described in the offer document.
| Metric | 31-Mar-26 | 31-Mar-25 | 31-Mar-24 |
|---|
Molbio Diagnostics Limited finalised its anchor investor allocation on August 7, 2026, raising ₹281.46 crore from 33 institutional investors at an anchor price of ₹807 per share. The anchor book comprises 34,87,717 equity shares allocated across domestic mutual funds, life insurance companies, and foreign portfolio investors.
Domestic mutual funds received 67.51% of the anchor allocation through 9 fund houses across 19 schemes, including HDFC Mutual Fund, Kotak Mahindra Mutual Fund, ICICI Prudential Mutual Fund, Nippon India Mutual Fund, Mirae Asset Mutual Fund, WhiteOak Capital Mutual Fund, Motilal Oswal Mutual Fund, Tata Mutual Fund, and Edelweiss Mutual Fund. Life insurance companies received 7.62% of the allocation, comprising Bajaj Life Insurance Limited, Axis Max Life Insurance Limited (across 8 fund/pension schemes), and HDFC Life Insurance Company Limited.
Leading foreign portfolio investors include Goldman Sachs Funds at 8.88%, International Finance Corporation at 7.11%, BlackRock Global Funds – India Fund at 7.11%, and Goldman Sachs ETF Trust at 1.78%.
Chandrasekhar Bhaskaran Nair, Exxora Trading LLP, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, Sriram Natarajan.
Work out the listing gain for this IPO
If the retail portion is not fully subscribed, every valid application is allotted in full. If it is oversubscribed, SEBI's rules require that as many applicants as possible receive at least one lot, so the shares are allotted by a computerised lottery across all valid applications, one lot each, until the retail portion is exhausted. Applying for more lots does not improve your chance in a lottery; it only increases what you receive if the issue is under-subscribed.
The basis of allotment document, published by the registrar on the allotment date, states the ratio: for example, one applicant in seven received one lot.
Allotment status is published by the registrar on its website, searchable by PAN, application number or demat account, and also on the exchange's website. Allotted shares are credited to the demat account the day before listing, and blocked money for unsuccessful applications is released the same day. The Rupix app can check allotment status by PAN once the registrar publishes it.
Shares list within three working days of the issue closing. On listing day the exchanges run a special pre-open session from nine o'clock, during which orders are collected and an opening price is discovered from them; trading in the share begins after that, usually around ten. The opening price is the listing price that appears on this page once the issue has listed, and the listing gain or loss is the difference between it and the issue price.
For a mainboard issue, the share then trades in the normal way with the exchange's price band for a new listing. For an SME issue, shares trade in lots rather than one at a time, and the market can be thin, so selling on listing day is not always possible at the opening price. Capital gains on shares sold within a year of allotment are short-term and taxed at the short-term rate.
Molbio Diagnostics IPO was a ₹939.7 crore book-built issue, comprising a fresh issue of ₹200 crore and an offer for sale of ₹739.7 crore. It was priced at ₹768–₹807 per share with a lot size of 18 shares (₹14,526). The IPO was open from August 10 to August 12, 2026 and was subscribed 70.26x. Shares listed on BSE and NSE on August 17, 2026 at ₹980, a 21.4% premium to the issue price of ₹807. Kfin Technologies Ltd.
is the registrar. Kotak Mahindra Capital Co.Ltd. and 3 other book running lead managers manage the issue.
The price band of Molbio Diagnostics IPO is ₹768 to ₹807 per share.
The lot size of Molbio Diagnostics IPO is 18 shares.
The minimum investment for Molbio Diagnostics IPO is approximately ₹14,526 based on the upper price band.
The allotment date of Molbio Diagnostics IPO is Aug 13, 2026.
No GMP quote could be verified as recorded before Molbio Diagnostics IPO listed. A grey-market observation of ₹120 per share was recorded on 17 Aug 2026, 8:30 AM IST, but without a verified listing timestamp it is not treated as the final pre-listing GMP. The shares listed at ₹980. GMP is unofficial and does not forecast or guarantee the actual listing price.
Molbio Diagnostics IPO listed on Aug 17, 2026. It was issued at ₹980.0(NSE) and is currently around ₹1270.00 as on 30-Oct-2026 3:30 PM, which is approximately 57.4% versus issue price. The 52-week high is ₹1,686.80.
You can check Molbio Diagnostics IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Molbio Diagnostics IPO allotment status on Rupix for quick and easy access.
₹768 to ₹807 per share, against a face value of ₹1. Most applicants bid at the cut-off price, the top of the band, so that the application was valid whatever price the issuer finally fixed.
One lot was 18 shares, and every application had to be a whole number of lots. At the top of the band that made the minimum application ₹14,526.
₹14,526, for one lot of 18 shares at the top of the price band. The amount was blocked in the applicant's bank account through ASBA or a UPI mandate while the issue was open, and released on the allotment date to applicants who were not allotted shares.
It opened on 10 August 2026 and closed on 12 August 2026.
The basis of allotment was published on 13 August 2026 by Kfin Technologies Ltd, and allotted shares were credited to demat accounts before listing.
The shares listed on 17 August 2026 on BSE, NSE, opening at ₹980.
The issue size was ₹939.7 crore. The fresh issue was 24,80,246 shares (aggregating up to ₹200 crore). The offer for sale was 91,66,000 shares (aggregating up to ₹739.7 crore).
It listed at ₹980 against an issue price of ₹807, a gain of 21.4 percent on listing day.